EGFR and non-small cell lung carcinoma: Furthermore, mobocertinib has been voluntarily withdrawn after a reassessment of its overall benefit-risk profile, leaving amivantamab as the principal approved targeted option for many patients with EGFR ex20ins-mutant NSCLC (14, 17).